New therapeutic targets for osteoporosis

Beyond denosumab

Vivien Lim, Bart Clarke

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Treatments for osteoporosis over the last few decades have largely focused on antiresorptive agents that effectively prevent bone loss. Beginning with hormone therapy, a variety of new potent antiresorptive agents were developed, including oral and intravenous bisphosphonates, raloxifene and other selective estrogen receptor modulators, nasal spray calcitonin, and denosumab. Teriparatide and PTH 1-84 are the only approved anabolic agents to date that primarily build new bone density. A variety of new biologic agents that focus on molecular targets important for the stimulation of new bone formation are being developed. Cathepsin K inhibitors appear to have mixed antiresorptive and anabolic actions because they inhibit one of the major osteoclast digestive enzymes without suppressing bone formation, thereby leading to anabolic effects on bone. New biologic agents in clinical trials include anti-sclerostin and anti-dickkopf antibodies that stimulate the Wnt/β-catenin pathway in osteoblasts, leading to new bone formation. These new agents will effectively stimulate new bone formation by different mechanisms, leading to improved bone mineral density and reduced fractures.

Original languageEnglish (US)
Pages (from-to)269-272
Number of pages4
JournalMaturitas
Volume73
Issue number3
DOIs
StatePublished - Nov 1 2012

Fingerprint

Osteogenesis
Osteoporosis
Bone
Bone Density Conservation Agents
Anabolic Agents
Biological Factors
Bone Density
Cathepsin K
Teriparatide
Nasal Sprays
Selective Estrogen Receptor Modulators
Bone and Bones
Catenins
Wnt Signaling Pathway
Diphosphonates
Calcitonin
Osteoclasts
Therapeutics
Parathyroid Hormone
Osteoblasts

Keywords

  • Anti-dickkopf antibody
  • Anti-sclerostin antibody
  • Cathepsin K inhibitors
  • Osteoporosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

New therapeutic targets for osteoporosis : Beyond denosumab. / Lim, Vivien; Clarke, Bart.

In: Maturitas, Vol. 73, No. 3, 01.11.2012, p. 269-272.

Research output: Contribution to journalReview article

Lim, Vivien ; Clarke, Bart. / New therapeutic targets for osteoporosis : Beyond denosumab. In: Maturitas. 2012 ; Vol. 73, No. 3. pp. 269-272.
@article{eec786c2bd894675b78b79c4158ac220,
title = "New therapeutic targets for osteoporosis: Beyond denosumab",
abstract = "Treatments for osteoporosis over the last few decades have largely focused on antiresorptive agents that effectively prevent bone loss. Beginning with hormone therapy, a variety of new potent antiresorptive agents were developed, including oral and intravenous bisphosphonates, raloxifene and other selective estrogen receptor modulators, nasal spray calcitonin, and denosumab. Teriparatide and PTH 1-84 are the only approved anabolic agents to date that primarily build new bone density. A variety of new biologic agents that focus on molecular targets important for the stimulation of new bone formation are being developed. Cathepsin K inhibitors appear to have mixed antiresorptive and anabolic actions because they inhibit one of the major osteoclast digestive enzymes without suppressing bone formation, thereby leading to anabolic effects on bone. New biologic agents in clinical trials include anti-sclerostin and anti-dickkopf antibodies that stimulate the Wnt/β-catenin pathway in osteoblasts, leading to new bone formation. These new agents will effectively stimulate new bone formation by different mechanisms, leading to improved bone mineral density and reduced fractures.",
keywords = "Anti-dickkopf antibody, Anti-sclerostin antibody, Cathepsin K inhibitors, Osteoporosis",
author = "Vivien Lim and Bart Clarke",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.maturitas.2012.08.002",
language = "English (US)",
volume = "73",
pages = "269--272",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - New therapeutic targets for osteoporosis

T2 - Beyond denosumab

AU - Lim, Vivien

AU - Clarke, Bart

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Treatments for osteoporosis over the last few decades have largely focused on antiresorptive agents that effectively prevent bone loss. Beginning with hormone therapy, a variety of new potent antiresorptive agents were developed, including oral and intravenous bisphosphonates, raloxifene and other selective estrogen receptor modulators, nasal spray calcitonin, and denosumab. Teriparatide and PTH 1-84 are the only approved anabolic agents to date that primarily build new bone density. A variety of new biologic agents that focus on molecular targets important for the stimulation of new bone formation are being developed. Cathepsin K inhibitors appear to have mixed antiresorptive and anabolic actions because they inhibit one of the major osteoclast digestive enzymes without suppressing bone formation, thereby leading to anabolic effects on bone. New biologic agents in clinical trials include anti-sclerostin and anti-dickkopf antibodies that stimulate the Wnt/β-catenin pathway in osteoblasts, leading to new bone formation. These new agents will effectively stimulate new bone formation by different mechanisms, leading to improved bone mineral density and reduced fractures.

AB - Treatments for osteoporosis over the last few decades have largely focused on antiresorptive agents that effectively prevent bone loss. Beginning with hormone therapy, a variety of new potent antiresorptive agents were developed, including oral and intravenous bisphosphonates, raloxifene and other selective estrogen receptor modulators, nasal spray calcitonin, and denosumab. Teriparatide and PTH 1-84 are the only approved anabolic agents to date that primarily build new bone density. A variety of new biologic agents that focus on molecular targets important for the stimulation of new bone formation are being developed. Cathepsin K inhibitors appear to have mixed antiresorptive and anabolic actions because they inhibit one of the major osteoclast digestive enzymes without suppressing bone formation, thereby leading to anabolic effects on bone. New biologic agents in clinical trials include anti-sclerostin and anti-dickkopf antibodies that stimulate the Wnt/β-catenin pathway in osteoblasts, leading to new bone formation. These new agents will effectively stimulate new bone formation by different mechanisms, leading to improved bone mineral density and reduced fractures.

KW - Anti-dickkopf antibody

KW - Anti-sclerostin antibody

KW - Cathepsin K inhibitors

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84867336111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867336111&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2012.08.002

DO - 10.1016/j.maturitas.2012.08.002

M3 - Review article

VL - 73

SP - 269

EP - 272

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 3

ER -